Hepion Pharmaceuticals Inc (HEPA NASDAQ) stock market data APIs
$0.0684
0(0%)
as of July 1, 2025
Try our APIs with
free plan!
Hepion Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC) and other chronic liver diseases in the United States. It develops Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, HDV, and HIV-1. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.
Prev. Close
0.0684
Open
0.0719
High
0.0993
Low
0.0574
52 wk Range
0.0381-56
Market Cap
877 K
Shares Outstanding
10 976 K
EPS
-11.1193
Beta
1.552
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Hepion Pharmaceuticals Inc data using free add-ons & libraries
Get Hepion Pharmaceuticals Inc Fundamental Data
Hepion Pharmaceuticals Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -15 437 166
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-26
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Hepion Pharmaceuticals Inc News
New
Hepion Pharmaceuticals Appoints Kaouthar Lbiati As Interim CEO
(RTTNews) - Hepion Pharmaceuticals, Inc. (HEPA) said on Monday that it has appointed Kaouthar Lbiati as interim Chief Executive Officer with effect from June 16 after John Brancaccio decided...
Hepion Pharmaceuticals appoints Kaouthar Lbiati as interim CEO
* Hepion Pharmaceuticals (OTC:HEPA [https://seekingalpha.com/symbol/HEPA]) announced that Kaouthar Lbiati has been named as interim chief executive officer (CEO), effective June 16, 2025. * The co...
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steat...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Protect Your Portfolio Against Market Uncertainty Disco...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
